Charles River to Acquire Vigene Biosciences
We are pleased to announce plans to acquire Vigene Biosciences, a premier, gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. The planned acquisition will expand Charles River’s cell and gene therapy CDMO capabilities for viral vectors and plasmid DNA.
Vigene’s primary area of expertise is cGMP viral vector manufacturing, which is used for gene therapies and gene-modified cell therapies. Vigene has significant expertise in adeno-associated virus (AAV) cGMP production, which is the most commonly used delivery solution for gene therapies, as well as for other major viral vectors, including lentivirus. Vigene also offers high-quality, research grade and cGMP plasmid DNA, which is a foundational tool used in the development of viral vectors for gene-modified cell therapies, gene therapies, and vaccine production.
The addition of Vigene will be complementary to Charles River’s existing, non-clinical development and manufacturing capabilities and provide clients access to a comprehensive cell and gene therapy solution. Combined with our integrated portfolio of manufacturing support services, including biologics safety testing, cell supply and release testing, this acquisition will enhance Charles River’s gene therapy capabilities in this high-growth, value-added cell and gene therapy CDMO sector.